Within this network fundamental and clinical researchers closely collaborate in the field of individualised therapy development.
The U-PGx consortium addresses major challenges and obstacles for implementation of PGx testing in patient care, taking into account the diversity of healthcare systems and citizens across Europe. Specifically, U-PGx investigates if the emerging approach of pre-emptive genotyping of an entire panel of important PGx markers is cost-effective and results in a better outcome for patients. Our main goal is to improve the safety and efficacy of pharmacotherapy for every European patient by enabling clinical pharmacogenomics. Based on the findings of the U-PGx project we will formulate European strategies for improving clinical implementation of pharmacogenomics. This project is funded by the European Community’s Horizon 2020 Programme under grant agreement No. 668353.
PGRN Hub & the Featured Investigator